All Insights

Anthropic's revenue model routes cleanly into VGT with no ambiguity. OpenAI's classification is genuinely uncertain — its $100M advertising business is tiny today, but if it scales toward its stated $100B 2030 target, a 2027 reclassification into VOX becomes plausible.

VGT's top 5 holdings make up ~53% of the fund — yet Alphabet, Meta, and Amazon aren't among them, excluded by a GICS classification rule, not an oversight. What "diversified tech exposure" actually means once you look at what's in, and what's out.

Cell and gene therapy generated over $14B in 2024, yet pharma spent $10B+ acquiring pre-commercial companies in just seven months. The "CGT is dead" narrative confuses a broken pricing model with failed science — the biology already works.

Investment banks can't predict whether a drug will work — 50-70% of Phase 2 drugs fail before Phase 3, yet banks price pre-Phase 3 biotech IPOs on a 16-20 week timeline anyway. VC, IB, and PE each play a genuinely different role — only one is actually built to judge the science.

A PE-owned nursing home chain study found a 10% rise in resident mortality — over 20,000 additional deaths — while financial metrics kept improving. Why private equity can be excellent at what it does and still be structurally unable to catch a scientific inflection before it's too late.

Understanding a sector and knowing how to size a position in it are two different skills. A framework for where AI/tech, pharma, gold, silver, and bitcoin each belong — core, satellite, or alternatives — and how much of your portfolio each deserves.

Silver is now 59% industrial demand, up from 50% a decade ago — yet industrial demand and price show almost no meaningful correlation. Fifty years of data point to one honest description: a random walk with drift, unpredictable short-term, with a real upward trend measured in decades.

Buffett turned $230 million into a 4,300% return on BYD H-shares over 17 years — with zero capital controls on the exit. Three practical routes for retail investors to own Chinese innovation directly, from Hong Kong H-shares to US-listed ETFs and ADRs.

Buffett's 4,300% BYD return and Son's 425x on Alibaba have one thing in common: neither touched China's onshore capital controls. A vehicle-by-vehicle map — from Bond Connect to H-shares to offshore PE — showing institutions and family offices how to access China's growth with the cleanest possible repatriation.

Nvidia lost $589 billion in a single session on the DeepSeek news — the largest one-day market cap loss in history — then recovered 9% the next day. The narrative never broke; only the price moved. A framework for reading fame-driven dips in Apple, Tesla, Nvidia, and Meta as opportunities, not warnings.